SUBSCRIBE
SUBSCRIBE

Phase 2

Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
In Response to Twitter Rumors and Phase II Data, Verastem Stock Plunges
August 27, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Esperion Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval
August 18, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial
August 17, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Avalanche Biotech Goes Back to Drawing Board, Performs More Preclinical Studies on Eye Drug
August 14, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech, AbbVie Confirm Venetoclax Met Primary Endpoint in Phase II Study
August 12, 2015
 · 
3 min read
Drug Development
Bay Area’s XOMA (US) LLC to Cut Jobs and Change Focus in Light of Q2 Filings and Stock Drop
August 7, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Embattled Vitae Pharma and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s
July 27, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Amgen Lauds Positive Phase II Data for Leukemia Drug Blincyto
July 17, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Zogenix and FDA Delay Two Rare Epilepsy Trials by Three Months
July 15, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s Breakthrough Atezolizumab Joins Club of Successful Anti-PD-L1 Drugs, Shrinks Tumors in Bladder Cancer
July 13, 2015
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
July 10, 2026
 · 
4 min read
Press Releases
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
July 9, 2026
 · 
6 min read
Press Releases
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
July 9, 2026
 · 
4 min read
Press Releases
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
July 9, 2026
 · 
7 min read
Press Releases
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
July 9, 2026
 · 
9 min read
Press Releases
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
 · 
7 min read
Press Releases
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 9, 2026
 · 
6 min read
Press Releases
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
July 9, 2026
 · 
3 min read
Press Releases
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
July 8, 2026
 · 
6 min read
Press Releases
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
July 8, 2026
 · 
6 min read
Press Releases
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
July 8, 2026
 · 
21 min read
Press Releases
Eradivir Doses First Influenza Patient With EV25 in Bangladesh Study
July 7, 2026
 · 
3 min read
Press Releases
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease
July 7, 2026
 · 
4 min read
Press Releases
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026
 · 
5 min read
Press Releases
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
July 7, 2026
 · 
4 min read
Press Releases
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 7, 2026
 · 
10 min read
Press Releases
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
July 7, 2026
 · 
9 min read
Press Releases
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
July 7, 2026
 · 
10 min read
Press Releases
CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types
July 7, 2026
 · 
4 min read
Press Releases
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
July 7, 2026
 · 
4 min read
Load More